Amir Moheet, MBBS

Associate Professor of Medicine, Division of Diabetes, Endocrinology and Metabolism

Amir Moheet

Contact Info

Mailing Address:
420 Delaware Street SE
MMC 101
Minneapolis, MN 55455

Administrative Assistant Name
Pam Wenner

Administrative Email
wenne164@umn.edu

Associate Professor of Medicine, Division of Diabetes, Endocrinology and Metabolism


Endocrinologist


MD, Medical School, Dow Medical College, Karachi, Pakistan

Residency, State University of New York, at Buffalo, Buffalo, NY

Fellowship, University of Minnesota, Minneapolis, MN

Summary

Dr. Amir Moheet graduated from Dow Medical College in Karachi, Pakistan. He completed his Internal Medicine residency training and was chief resident at State University of New York at Buffalo, NY. He completed his Endocrinology fellowship from University of Minnesota in 2012. Dr. Moheet is currently an Associate Professor in Division of Endocrinology, Diabetes and Metabolism at University of Minnesota. He is actively engaged in clinical and translational research. His research is focused on examining the effects of diabetes and its complications on brain metabolism, structure and function. His clinical and research interests also include cystic fibrosis related diabetes.

Awards & Recognition

  • Mpls St.Paul Magazine "Top Doctor - Rising Star" (2015)
  • Selected in the EnVision CF: Emerging Leaders in Cystic Fibrosis Endocrinology Program by the Cystic Fibrosis Foundation. (2016 )
  • Elected for lifetime membership in the University of Minnesota Office of Academic Clinical Affairs Academy for Excellence in Team Science. (2019)

Research

Research Summary/Interests

  • Examine the effects of diabetes, hypoglycemia, and obesity on brain structure and function.
  • Develop novel treatment options for the prevention and treatment of impaired awareness of hypoglycemia.
  • Understand the pathogenesis on hypoglycemia in cystic fibrosis
  • Developing novel strategies for management of diabetes in obese or overweight people with cystic fibrosis

Publications

  • Moheet A, Emir UE, Terpstra M, Kumar A, Eberly LE, Seaquist ER, Oz G. Initial experience with seven tesla magnetic resonance spectroscopy of hypothalamic GABA during hyperinsulinemic euglycemia and hypoglycemia in healthy humans. Magn Reson Med. 2014 Jan;71(1):12-8. PMID: 23423963; PMCID: PMC3665652
  • Moheet A, Kumar A, Eberly LE, Kim J, Roberts R, Seaquist ER. Hypoglycemia associated autonomic failure in healthy humans: Comparison of two vs three periods of hypoglycemia on hypoglycemia-induced counterregulatory and symptom response 5 days later. J Clin Endocrinol Metab. 2014 Feb;99(2):664-70. PMID: 24423306; PMCID: PMC3913799
  • Moheet A, Mangia S, Kumar A, Tesfaye N, Eberly LE, Bai Y, Kubisiak K and Seaquist ER Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: A randomized clinical trial. Journal for diabetes and its complications. 2015 Nov-Dec;29(8):1277-82. PMID: 26345338; PMCID: PMC4871128
  • Moheet A, Mangia S, Seaquist ER. Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci. 2015 Sep;1353:60-71; PMID: 26132277; PMCID: PMC4837888
  • Moheet, A., Beisang, D., Zhang, L., Sagel, S., VanDalfsen, J., Heltshe, S., Frederick, C., Mann, M., Antos, N., Billings, J., Rowe, S., & Moran, A. (2020). PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. J Cyst Fibros 2020 Sep 8;S1569-1993(20)30862-6.

Clinical

Board Certifications

  • Internal Medicine
  • Endocrinology, Diabetes, and Metabolism

Clinical Interests

Type 1 and type 2 diabetes, General Endocrinology, Cystic fibrosis related diabetes